Do NAD+ Supplements Actually Work, or Is It Hype?

Short answer: Yes, for the one thing you can measure: oral NAD+ precursors (NR and NMN) reliably raise blood NAD+ levels in human trials, and that has been demonstrated repeatedly. The outcome research beyond blood levels is still catching up. The sublingual route exists precisely because intact NAD+ cannot survive digestion.

Most pages on this query are written by someone selling you a bottle. We sell NAD+ too — a sublingual strip — so consider that disclosed. What we can offer that a capsule brand can't: the full ledger, including the parts that don't flatter anyone. Category background lives in the NAD+ pillar.

First, define "work"

"Do NAD+ supplements work" hides two questions with two very different evidentiary bars:

1. Do they raise NAD+ levels in the body? Measurable with a blood test.
2. Does raising NAD+ produce the outcomes people buy it for — energy, healthy aging, resilience? That requires controlled outcome trials, a much higher bar.

Clearing bar one is already a genuine achievement — most supplement ingredients never demonstrate even that. And the NAD+ category has cleared it, repeatedly.

What's established in humans — and it's a lot

Oral NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — raise blood NAD+ levels in humans. That was shown for NR in a 2016 study (Trammell et al., Nature Communications) and in multiple randomized controlled trials of NMN at daily doses in the 250–900 mg range [published human data]. If the question is "can a supplement move this biomarker," the answer is yes, over and over, across research groups.

And the evidence is still compounding. A January 2026 head-to-head study (Christen et al., Nature Metabolism; n=65, 1,000 mg/day) found both NMN and NR arms roughly doubled blood NAD+, with no significant difference between them — two distinct precursor routes, converging on the same result [published human data]. That comparison has its own dedicated piece: NMN vs NR.

This is why the NAD+ conversation has staying power: the biology (NAD+ declines with age, it's central to cellular energy metabolism) plus the demonstrated ability to restore the biomarker is a genuinely strong starting point.

The intact-NAD+ problem — and why it created the strip

Here's the twist that shapes product design. Oral NR and NMN survive digestion well enough to work. Intact NAD+ does not — it's broken down in the gut, which is why the oral-supplement industry standardized on precursors [published human data].

That gut-survival problem is the honest rationale for the sublingual route: the mouth's mucosa offers a path that bypasses digestion entirely. It's a real mechanistic argument, and early delivery science is pointing in an encouraging direction — a rat pharmacokinetic study from iX Biopharma reported plasma NAD+ peaking at roughly twice baseline within 10 minutes of sublingual dosing, followed by a small company-sponsored human pilot reporting rising whole-blood NAD+ over six weeks [preclinical evidence + unpublished company pilot — not peer reviewed]. Early signal, not settled science — but a real signal. NAD+ is a large, charged molecule (~663 Da), which makes it the counterintuitive case where the direct molecule is the one that most needs a clever route; see molecular weight and sublingual delivery and does sublingual NAD+ work.

The honest context, stated once

Now the paragraph that doesn't help us sell anything, printed because you'd eventually find it anyway. Biomarker movement is demonstrated; downstream outcome benefits in healthy adults are not. A rigorous randomized trial of NR in long-COVID patients (Wu et al., 2025, NCT04809974; n=58, NR 2,000 mg/day, published in The Lancet's eClinicalMedicine) was null on its between-group primary endpoints versus placebo, with within-group symptom improvements the sponsor has promoted — a split result, not a win [published human data]. And no published human pharmacokinetic study exists yet for sublingual NAD+ strips as a consumer format, so the strip's rationale remains exactly that — a strong mechanistic rationale awaiting its definitive human trial. If your standard is "show me controlled human outcome data," the entire NAD+ category — ours included — is still working toward that bar. The precursor-versus-strip comparison is covered in NAD vs precursors and NAD+ side effects.

What the evidence shows — and what it doesn't

Established: oral NR and NMN raise blood NAD+ in humans across multiple controlled trials; intact NAD+ does not survive the gut; the sublingual route has a coherent mechanistic rationale plus early preclinical and pilot signals.

Not established: that raising NAD+ reliably produces the energy, aging, or performance outcomes marketing implies; that any sublingual NAD+ strip raises NAD+ in humans in a published trial; that more NAD+ is better for everyone.

Where the strip fits

If you explore NAD+, the strip format is at the NAD+ strips page — $118 per 30-strip box — with expectations set by everything above. It's the needle-free, gut-free format built on the strongest mechanistic case in the category.

The bottom line

Do NAD+ supplements work? The biomarker says yes — loudly, repeatedly, in human trials. The outcome story is still being written, and the delivery science is the most interesting chapter: the molecule that can't survive your stomach is exactly the molecule the mouth route was invented for. Pick the format that matches the mechanism, keep expectations calibrated, and bring a licensed provider into the loop.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.